A Phase 3, two-stage, randomized, multi-center, controlled, open-label study comparing iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM)

• Confirmed diagnosis of symptomatic multiple myeloma
• ECOG PS 0-2
• Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) [eg, bortezomib thalidomide and dexamethasone (VTd), lenalidomide, bortezomib and dexamethasone (RVd)] with or without a CD38 monoclonal antibody, or Velcade® (bortezomib), cyclophosphamide, dexamethasone (VCd), and followed by a single or tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant consolidation is permitted.
• Participants within 12 months from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria
• No PD or clinical replapse following ASCT or non-responsiveness to primary therapy
• No known CNS or meningeal involvement

• Primary
  • PFS
• Secondary
  • MRD negativity
  • OS
  • PK
  • Safety
  • TTP
  • TTNT
  • ORR
  • QOL